Accelerate Diagnostics Inc. (NASDAQ:AXDX) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $25.00 for the company and are forecasting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also given Accelerate Diagnostics an industry rank of 103 out of 265 based on the ratings given to its competitors.
Several brokerages recently issued reports on AXDX. BTIG Research reaffirmed a “buy” rating and set a $26.00 price target on shares of Accelerate Diagnostics in a report on Wednesday, June 15th. JPMorgan Chase & Co. lifted their price target on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the company an “overweight” rating in a report on Tuesday, August 9th. Finally, Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th.
Large investors have recently bought and sold shares of the company. Stifel Financial Corp acquired a new stake in Accelerate Diagnostics during the second quarter worth $487,000. Barclays PLC raised its stake in Accelerate Diagnostics by 137,400.0% in the second quarter. Barclays PLC now owns 86,625 shares of the company’s stock worth $1,247,000 after buying an additional 86,562 shares in the last quarter. KCG Holdings Inc. raised its stake in Accelerate Diagnostics by 123.9% in the second quarter. KCG Holdings Inc. now owns 24,114 shares of the company’s stock worth $347,000 after buying an additional 13,342 shares in the last quarter. Nuveen Asset Management LLC raised its stake in Accelerate Diagnostics by 14.5% in the second quarter. Nuveen Asset Management LLC now owns 710,571 shares of the company’s stock worth $10,225,000 after buying an additional 90,030 shares in the last quarter. Finally, Loomis Sayles & Co. L P purchased a new stake in Accelerate Diagnostics during the second quarter worth approximately $1,099,000. 35.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Accelerate Diagnostics (NASDAQ:AXDX) opened at 27.26 on Wednesday. The firm’s market capitalization is $1.40 billion. The company’s 50 day moving average is $24.42 and its 200-day moving average is $17.37. Accelerate Diagnostics has a one year low of $10.29 and a one year high of $28.50.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.